Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5

Author:

Murase Takuhei1,Yamaguchi Motoko2,Suzuki Ritsuro3,Okamoto Masataka4,Sato Yumiko5,Tamaru Jun-ichi6,Kojima Masaru7,Miura Ikuo8,Mori Naoyoshi9,Yoshino Tadashi5,Nakamura Shigeo9

Affiliation:

1. Department of Internal Medicine, Nishio Municipal Hospital, Nishio, Japan;

2. Department of Hematology, Mie University Graduate School of Medicine, Tsu, Japan;

3. Department of Hematopoietic Stem Cell Transplantation Data Management, Nagoya University School of Medicine, Nagoya, Japan;

4. Division of Hematology and Medical Oncology, Department of Medicine, Fujita Health University School of Medicine, Toyoake, Japan;

5. Department of Pathology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan;

6. Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan;

7. Department of Pathology and Clinical Laboratories, Gunma Cancer Center Hospital, Ota, Japan;

8. Department of Hematology and Oncology, St Marianne University School of Medicine, Kawasaki, Japan;

9. Department of Pathology and Biological Response, Nagoya University Graduate School of Medicine, Nagoya, Japan

Abstract

AbstractIntravascular large B-cell lymphoma (IVLBCL) is pathologically distinct with a broad clinical spectrum and immunophenotypic heterogeneity. A series of 96 patients with IVLBCL (median age, 67 years; range, 41-85 years; 50 men) was reviewed. Anemia/thrombocytopenia (84%), hepatosplenomegaly (77%), B symptoms (76%), bone marrow involvement (75%), and hemophagocytosis (61%) were frequently observed. The International Prognostic Index score was high or high-intermediate in 92%. For 62 patients receiving anthracycline-based chemotherapies, median survival was 13 months. CD5, CD10, Bcl-6, MUM1, and Bcl-2 were positive in 38%, 13%, 26%, 95%, and 91% of tumors, respectively. All 59 CD10− IVLBCL cases examined were nongerminal center B-cell type because they lacked the Bcl-6+MUM1− immunophenotype. CD5 positivity was associated with a higher prevalence of marrow/blood involvement and thrombocytopenia and a lower frequency of neurologic abnormalities among patients with CD10−IVLBCL. Compared with 97 cases of de novo CD5+CD10−diffuse LBCL, 31 cases of CD5+CD10−IVLBCL exhibited higher frequencies of poor prognostic parameters, except age. Multivariate analysis in IVLBCL revealed that a lack of anthracycline-based chemotherapies (P < .001, hazard ratio [HR]: 9.256), age older than 60 years (P = .012, HR: 2.459), and thrombocytopenia less than 100 × 109/L (P = .012, HR: 2.427) were independently unfavorable prognostic factors; CD5 positivity was not. Beyond immunophenotypic diversity, IVLBCL constitutes a unique group with aggressive behavior.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference26 articles.

1. Gatter KC and Warnke RA. World Health Organization: Pathology and Genetics of Tumors of Heamatopoietic and Lymphoid Tissues. Intravascular large B-cell lymphoma. 2001;In Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds.). Lyon, France IARC Press177–178.

2. Pfleger VL and Tappeiner J. Zur Kenntnis der systemisierten Endotheliomatose der cutanen Blutgefäße (Reticuloendotheliose?). Hautarzt1959; 10:363–369.

3. Murase T, Nakamura S, Tashiro K, et al. Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature. Br J Haematol1997; 99:656–664.

4. Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol2000; 111:826–834.

5. Gatter KC and Warnke RA. World Health Organization: Pathology and Genetics of Tumors of Heamatopoietic and Lymphoid Tissues. Diffuse large B-cell lymphoma. 2001;In Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds.). Lyon, France IARC Press171–174.

Cited by 360 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3